Get Full Government Meeting Transcripts, Videos, & Alerts Forever!
Get email alerts on the Public Health Immunizations topic
No spam. Unsubscribe anytime.
Heated testimony as New Hampshire panel weighs removing newborn hepatitis B from required vaccines
Summary
Supporters of HB1719 say the bill aligns state policy with updated ACIP guidance and restores parental choice; DHHS, physicians and medical groups warn removing the birth‑dose requirement risks reversing decades of progress against pediatric hepatitis B and could increase outbreak costs.
Representative Kelly Patenza introduced House Bill 1719, saying it would remove the universal newborn hepatitis B birth dose from the state’s list of required immunizations to match updated ACIP guidance and restore individualized, risk‑based decisionmaking. “This bill simply aligns state policy with that updated guidance,” Patenza told the Senate committee during the opening testimony.
Opponents included the Department of Health and Human Services (DHHS) and a string of pediatricians, infectious‑disease clinicians and medical organizations. Megan Hedi, the Bureau chief for Infectious Disease Control, told the committee that hepatitis B is highly infectious when blood exposure occurs and that infants infected perinatally face a high risk of chronic lifelong infection and subsequent liver disease. “Approximately 90% of infants infected with the hepatitis B virus will develop chronic infection,” Hedi said, noting DHHS estimates that a single outbreak response can cost “$100,000 to $350,000.”
Several clinicians described a marked fall in pediatric hepatitis B cases after the introduction of the newborn dose. Dr. Patricia Edwards, a pediatrician who testified in opposition, cited historical numbers and said the vaccine has driven infections from thousands of annual pediatric cases down to single digits nationally. She described the vaccine as a cost‑effective prevention tool and urged the committee to reject the bill.
Supporters framed the measure as protecting parental rights and avoiding unnecessary interventions in newborns whose mothers test negative. Patenza and other supporters argued prenatal screening, targeted vaccination and parental consent are reasonable substitutes in many cases and described concerns about safety monitoring and long‑term adverse‑event detection.
Public commenters gave mixed, often emotional testimony: some described alleged vaccine injuries following the birth dose and urged removal; many clinicians and public‑health representatives countered that surveillance systems and long‑term data support the safety and population benefits of the birth dose.
The committee heard repeated requests for additional data on screening coverage, outbreak frequency and the financial tradeoffs of prevention versus treatment. The department said it could follow up with more detailed cost and epidemiologic figures.
What happens next: the hearing record remained open for the committee’s consideration; no formal vote was recorded on the transcripted proceedings. The committee will weigh the competing claims about population‑level benefits, individual‑level risks, and practical impacts on prenatal screening and outbreak response costs.
